Hyponatremia is a common electrolyte disorder in hospitalized patients. Although there are a few case reports of hyponatremia following stem cell transplantation (SCT), no reports concerning the incidence are currently available. We describe the occurrence of hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following SCT. In a single center analysis of 140 patients, hyponatremia and SIADH were observed in 40 and 11.4% of patients, respectively, following SCT. Risk factors for SIADH included young age, transplantation from an HLAmismatched or unrelated donor, cord blood transplantation, and graft-versus-host disease prophylaxis with methyl prednisolone. Multivariate analysis revealed that transplantation from an HLA-mismatched donor and performance of SCT in a child below 4 years of age were risk factors for SIADH. For patients who underwent SCT from an HLA-mismatched or unrelated donor, those with SIADH showed a significantly higher overall survival rate (90.9 vs 40.2%) and event-free survival rate (77.8 vs 33.8%) compared to those without SIADH. Overall, our data show that hyponatremia and SIADH are relatively common complications following SCT, especially in children below 4 years of age and after SCT from an HLA-mismatched donor.
transplantation
Survival rates for patients with some hematological disorders, malignant disorders, immunodeficiencies, and metabolic disorders may be significantly improved by stem cell transplantation (SCT). However, many complications have been observed with this procedure, and attention to safety issues surrounding transplantation is of particular importance. Hyponatremia is a common electrolyte disturbance, which may affect up to 15% of hospitalized patients, and this condition has been extensively reviewed. [1] [2] [3] Although case reports on hyponatremia following SCT are available, 4, 5 there are no reports with regard to the incidence of hyponatremia following SCT. We have examined 140 patients who underwent SCT and then developed hyponatremia and, in some cases, the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Risk factors for hyponatremia and SIADH are presented.
Patients and methods
Between February 1988 and October 2003, a total of 140 pediatric patients (82 boys and 58 girls) with various hematological malignancies, metabolic abnormalities, and immunodeficiencies underwent SCT in our hospital. Of these, 48 had acute lymphoblastic leukemia (ALL), of whom 26 were in first complete remission (CR), 15 were in second CR, and seven were in third or later CR. Of 21 patients with acute myelogenous leukemia (AML), 11 were in first CR, seven were in second CR, and three were in third or later CR. The remaining 71 patients had other diseases as follows: aplastic anemia (AA) (22 patients), non-Hodgkin's lymphoma (NHL) (10 patients), myelodysplastic syndrome (eight), rhabdomyosarcoma (six), neuroblastoma (six), Wiskott-Aldrich syndrome (WAS) (five), chronic myelogenous leukemia (CML) (four), juvenile myelomonocytic leukemia (JMML) (three), and yolk sac tumor, hepatoblastoma, Hunter syndrome, Kostmann syndrome, X-linked hyper IgM syndrome, primitive neuroectodermal tumor, and Hurler-Scheie syndrome (one patient each).
Of the 140 patients, 96 received a bone marrow transplant (BMT), 25 received a peripheral blood stem cell transplant (PBSCT), four received BMT and PBSCT, and 15 received a cord blood stem cell transplant (CBSCT). Donors were HLA-matched siblings (49 patients), one-locus-mismatched siblings (two patients), three-loci-mismatched siblings (two), HLA-matched or HLA-mismatched parents (12) , HLA-matched unrelated donors (35), HLA one-locus-mismatched unrelated donors (eight), and two-loci-mismatched unrelated donors (one).
The remaining 31 patients underwent autotransplantation. With regard to conditioning, busulfan (BU)-containing regimens were used in 51 patients, total body irradiation (TBI)-containing regimens in 60 patients, melphalancontaining regimens in 40, cyclophosphamide (CY)-containing regimens in 86, and antilymphocyte globulincontaining regimens in 35 patients. As prophylaxis for graft-versus-host disease (GVHD), 63 patients received cyclosporin A and short-term methotrexate, four received cyclosporin A alone, 14 received cyclosporin A and methylprednisolone, 18 received tacrolimus and short-term methotrexate, six received methotrexate alone, and one patient received tacrolimus and methylprednisolone.
Data were analyzed as of October 1, 2003.
Evaluation of hyponatremia
Serum sodium was measured daily by a routine automated analyzer on morning serum taken from every SCT patient until day 40 after SCT. We defined hyponatremia as a serum sodium value of less than 130 mmol/l on 2 consecutive days. Furthermore, we defined severe hyponatremia as a serum sodium value of less than 125 mmol/l for 2 consecutive days.
Diagnosis of SIADH
SIADH was diagnosed using the approach reported by Bartter and Schwartz. 6 Diagnosis requires the presence of all of the following criteria: (1) hyponatremia with hypotonicity of plasma; (2) urine osmolality in excess of plasma osmolality; (3) increased renal sodium excretion; (4) absence of edema or volume depletion; and (5) normal renal and adrenal function.
Statistical analysis
A t-test or a w 2 test was used to compare patients with SIADH with those without SIADH. Analyses of overall survival and event-free survival were performed using the Kaplan and Meier method with differences compared using a log-rank test. Multivariate analysis stepwise regression was performed to explore the independent effect of variables, which showed a significant influence on univariate analysis. Statistical analyses were performed using SPSS II for Windows (release 11.0.1J, SPSS Japan Inc.). Po0.05 was considered to be statistically significant.
Results

Hyponatremia
Hyponatremia less than 130 mmol/l was a complication in 56 (40%) of the 140 SCT patients and severe hyponatremia was seen in 27 patients (19.3%). The median day of occurrence of hyponatremia was 19 days (range: 0-74 days) after SCT. Causes of hyponatremia were considered to be due to SIADH in 16 patients, infection in 14 patients, diarrhea with acute GVHD in four patients, VOD in three patients, acute renal failure in four patients, influence of drugs in one patient, and enterocolitis with cytomegalovirus in one patient. Hyponatremia was of unknown cause in 13 patients.
Syndrome of inappropriate secretion of antidiuretic hormone
SIADH occurred in 16 (11.4%) of the 140 patients, and a summary of the backgrounds of the SIADH patients is provided in Table 1 . Of these 16 patients, eight had received CBSCT and 10 had undergone transplantation from a mismatched donor. In contrast, transplantation from an HLA-matched sibling donor had only been performed in one (6.3%) of the 16 patients. Symptoms of hyponatremia included seizures in two patients and nausea and vomiting in 13 patients. Risk factors for SIADH were examined and the following factors were identified: younger age, transplantation from an HLA-mismatched or unrelated donor, cord blood transplantation, and GVHD prophylaxis with methylprednisolone (Po0.01) ( Table 2 ). Drugs used in the conditioning regimen were not associated with SIADH. Multivariate analysis revealed that children below 4 years of age and transplantation from an HLA-mismatched donor were particular risk factors for SIADH (Po0.05) ( Table 3) .
In 60 patients (with a mixture of malignant and nonmalignant conditions) who underwent SCT from an unrelated donor or an HLA-mismatched donor, overall survival was superior in patients with SIADH compared to those without SIADH (P ¼ 0.0037) (Figure 1a ). In these patients, SIADH is the only factor associated with survival time using multivariate analysis (Table 4) . Of the 42 patients with a malignant disease, a comparison of those who developed SIADH with those without SIADH revealed a statistically significant difference in event-free survival (P ¼ 0.0337) (Figure 1b) .
Discussion
Hyponatremia is a common electrolyte disturbance in clinical practice and is defined as a decrease in serum sodium concentration to a level below 136 mmol/l. Causes of hyponatremia are various. 7, 8 The most frequent causes are extrarenal sodium loss due to vomiting or diarrhea, hepatic cirrhosis, drug-induced hyponatremia, and SIADH. Hypovolemic disorders due to extrarenal or renal sodium loss are the principal causes of hyponatremia, and headache, nausea, vomiting, muscle cramps, lethargy, restlessness, disorientation, and depressed reflexes may be observed if the hyponatremia is progressive. Complications of severe and rapidly evolving hyponatremia include seizures, coma, permanent brain damage, respiratory arrest, brain stem herniation, and death. The consequences of acute hyponatremia are more serious in young children and premenopausal women. 9 To our knowledge, only a few reports with regard to hyponatremia after SCT are available, 4, 5 and our report is the first one to describe risk factors for SIADH after SCT. In our study, 40% of patients, a surprisingly large number, experienced the complication of hyponatremia after SCT.
The causes of hyponatremia were diarrhea, infection, renal failure, SIADH among other things. Diarrhea, in particular, is a relatively frequent complication of SCT because of mucosal damage, infection, and acute GVHD, and hyponatremia due to diarrhea is, therefore, frequently observed after SCT. However, the rate of occurrence of SIADH, which was found in 16 (11.4%) of 140 SCT patients in the present study, was unexpectedly high. Hyponatremia related to SIADH has been associated with various antineoplastic agents, including vincristine, CY, ifosfamide, and thiotepa. 10, 11 However, our analysis showed that drugs and radiation used during conditioning were not associated with SIADH. SIADH has also been reported to be associated with several hematological diseases such as NHL and Hodgkin's disease. [12] [13] [14] [15] The most common cause of SIADH in NHL is thought to be either vinca alkaloid-containing chemotherapy or direct invasion into the pituitary gland. Chubati et al 12 have reported three cases of NHL in association with hemophagocytic syndrome and SIADH and have proposed an attractive alternative hypothesis. One of their patients with B-cell NHL had received no chemotherapy prior to the onset of SIADH. In this patient, they speculated that certain cytokines, such as IL-1b and TNF-a, stimulate hypothalamic synthesis and lead to the release of both ADH and corticotropin-releasing hormone (CRH). CRH induces the secretion of corticotropin and cortisol, which in turn suppress secretion of endogenous ADH. Following SCT, it has been reported that cytokines such as IL-2 and IFN-g enhance T-cell expansion, induce responses of cytotoxic T cells and natural killer cells, and prime additional mononuclear phagocytes to produce TNF-a and IL-1. 16, 17 In this context, therefore, the mechanism underlying development of SIADH after SCT may be due to the action of released cytokines.
SCT from an HLA-mismatched donor and performance of the procedure in younger children emerged as risk factors for SIADH in our analysis. SCT from an HLAmismatched donor or an unrelated donor is frequently complicated by severe GVHD, and levels of cytokines such as TNF-a and IL-6 are known to be high. 18 SIADH occurred from 16 to 74 days after SCT in our patient population, and this time lag is consistent with the time required for the development of acute GVHD. These cytokines may induce SIADH, although acute GVHD itself was not associated with the occurrence of SIADH (Table 2) . With regard to the age risk factor, alterations in sodium concentration usually reflect an abnormality in the handling of water, and the water content of young children is relatively higher than that of adults. The daily consumption of fluid by a healthy infant is equivalent to 10-15% of its body weight compared to 2-4% for adults. Accordingly, electrolyte imbalances occur more easily in infants than in adults, and SIADH may correspondingly occur more readily in infants.
Patients with SIADH showed apparently higher survival rates than those without SIADH, but the reasons for this are unknown. Hence, further studies using accumulated data from SIADH cases will be necessary to address this issue. In summary, our data show that hyponatremia and SIADH are relatively common after SCT, especially in children below 4 years of age and after SCT from an HLAmismatched donor. 
